Holen Sie sich die Stockscreener-App
1.235
4.66%
0.055
Schlusskurs vom Vortag:
$1.18
Offen:
$1.25
24-Stunden-Volumen:
96,726
Relative Volume:
0.70
Marktkapitalisierung:
$13.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.70M
KGV:
-1.1227
EPS:
-1.1
Netto-Cashflow:
$-8.57M
1W Leistung:
-17.67%
1M Leistung:
-28.20%
6M Leistung:
-55.49%
1J Leistung:
-72.37%
1-Tages-Spanne:
$1.1597
$1.30
1-Wochen-Bereich:
$1.13
$1.99
52-Wochen-Spanne:
$1.13
$5.99
Marker Therapeutics Inc Stock (MRKR) Company Profile
Firmenname
Marker Therapeutics Inc
Sektor
Branche
Telefon
(713) 400-6400
Adresse
2450 HOLCOMBE BLVD, HOUSTON, TX
Vergleichen Sie MRKR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.235 | 13.23M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.77 | 129.62B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
666.87 | 72.91B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
604.96 | 36.76B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.76 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.19 | 27.86B | 3.32B | -860.46M | -1.04B | -8.32 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-03-01 | Eingeleitet | Janney | Buy |
| 2018-12-03 | Hochstufung | Piper Jaffray | Neutral → Overweight |
Alle ansehen
Marker Therapeutics Inc Aktie (MRKR) Neueste Nachrichten
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MRKR stock touches 52-week low at $1.35 amid market challenges - Investing.com Australia
MRKR stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
Canaccord Genuity Group Initiates Coverage on Marker Therapeutics (NASDAQ:MRKR) - Defense World
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga India
Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation - Nasdaq
Marker Therapeutics initiated with a Buy at Canaccord - TipRanks
MRKR stock touches 52-week low at $1.45 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.45 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Will Marker Therapeutics Reveal New Clinical Data at Upcoming Cell Therapy Conference? - StockTitan
MRKR stock touches 52-week low at $1.48 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics grants stock options to CEO and directors By Investing.com - Investing.com South Africa
Marker Therapeutics grants stock options to CEO and directors - Investing.com India
Marker Therapeutics (MRKR) Stock Price, News & Analysis - MarketBeat
Analysts Offer Predictions for MRKR FY2024 Earnings - Defense World
Marker Therapeutics (NASDAQ:MRKR) Upgraded at Brookline Capital Management - Defense World
Brookline Capital sets $4 target on Marker Therapeutics stock - MSN
MRKR stock touches 52-week low at $1.61 amid market challenges - Investing.com Nigeria
Brookline Capital sets $4 target on Marker Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
MRKR stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 2.8% – Here’s Why - Defense World
Cytokinetics draws new Buy from Citi on aficamten potential - MSN
Biotech Analysis Central Model 10+ Portfolio Pick#16 Marker Therapeutics; MT-601 Lymphoma Data 2nd Half Of 2024, Study Initiation Of OTS MT-401 For AML And Catalysts (NASDAQ:MRKR) - Seeking Alpha
Marker Therapeutics Announces Board Resignation - MSN
MRKR stock touches 52-week low at $1.8 amid market challenges - MSN
Marker Therapeutics Announces Board Resignation By Investing.com - Investing.com Nigeria
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset - MSN
Hematopoietic Stem Cell Transplantation Market: Soaring - openPR
MRKR stock touches 52-week low at $2.4 amid challenging year - MSN
MRKR stock touches 52-week low at $2.4 amid challenging year By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next? - Defense World
SEC Form 424B3 filed by Marker Therapeutics Inc. - Quantisnow
BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers - Business Wire
Finanzdaten der Marker Therapeutics Inc-Aktie (MRKR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Marker Therapeutics Inc-Aktie (MRKR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, | 10% Owner |
Dec 23 '24 |
Buy |
3.20 |
554,250 |
1,773,600 |
1,625,678 |
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):